Feb. 5 at 7:47 PM
$AUPH should be competitive... PG Q2 2025: "As we said on our previous call our goal would be to try to get it in the most patient friendly potential formulation and device possible and that could include an auto injector. And we actually think looking at the doses we’ve seen to date, the molecular size that we have we could have the possibility to do that. But obviously once you’re in single ascending dose studies, you’re not optimized towards or at least we haven’t to those formulations yet. And that’s it’s parallel pathing with the development work that we’re doing. But everything points to us being able to from what we’ve seen in the single ascending dose and in the preclinical work group done up to this point that those goals would be attainable."
